14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PTGX vs AVDL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Protagonist Therapeutics, Inc (PTGX) on higher Unified Composite conviction (62.9/100 BUY vs. 44.6/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while PTGX wins 5–1 across the 6-pillar growth and valuation breakdown. PTGX trades at $121.40 (36.9x Forward P/E, 58.6% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin).
Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. PTGX 44.6/100 HOLD) and 0.14β · 2% Vol risk profile, whereas PTGX leads top-line expansion (+5723.6% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: PTGX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.4); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PTGX vs AVDL. Trailing 12-month operating profitability (PTGX 58.6% vs AVDL 2.5%) and valuation multiples (PTGX 36.9x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PTGX vs AVDL Key Questions & Quantitative Answers
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Protagonist Therapeutics, Inc (PTGX) on higher Unified Composite conviction (62.9/100 BUY vs. 44.6/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while PTGX wins 5–1 across the 6-pillar growth and valuation breakdown. PTGX trades at $121.40 (36.9x Forward P/E, 58.6% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. PTGX 44.6/100 HOLD) and 0.14β · 2% Vol risk profile, whereas PTGX leads top-line expansion (+5723.6% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: PTGX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.4); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PTGX leads the Growth & Scale pillar: PTGX posts +5723.6% YoY revenue growth and +351.3% YoY earnings growth on $552M TTM revenue (99.8% gross margin, 58.6% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, PTGX generates $552M in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, PTGX deploys 41.2% of Rev ($227M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.
AVDL screens cheaper on headline valuation multiples. PTGX trades at 36.9x Forward P/E, 26.2x Trailing P/E, N/M PEG, and 13.8x EV/Revenue (19.8% FCF margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTGX (39.6% ROE) versus AVDL (-0.3% ROE) capital efficiency.
In options market volatility and institutional positioning, PTGX carries 103.2% implied volatility (16th %ile, Compressed (<25th %ile)), a 2.89x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.97β · 36% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.